Signed in
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
| No holders yet. | ||||||||||
GS-6707, a medicinal product in development, targets severe respiratory infections like RSV by inhibiting viral replication. Aiming to reduce symptoms in high-risk groups, it's currently in preclinical trials.